QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

Progyny (PGNY) Stock Price, News & Analysis

$34.65
-6.14 (-15.05%)
(As of 02/28/2024 ET)
Today's Range
$33.07
$36.45
50-Day Range
$34.65
$41.62
52-Week Range
$29.44
$44.95
Volume
4.08 million shs
Average Volume
753,222 shs
Market Capitalization
$3.32 billion
P/E Ratio
66.64
Dividend Yield
N/A
Price Target
$48.30

Progyny MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
39.4% Upside
$48.30 Price Target
Short Interest
Bearish
7.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Progyny in the last 14 days
Based on 34 Articles This Week
Insider Trading
Selling Shares
$12.05 M Sold Last Quarter
Proj. Earnings Growth
19.30%
From $0.57 to $0.68 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

125th out of 959 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

1st out of 6 stocks


PGNY stock logo

About Progyny Stock (NASDAQ:PGNY)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

PGNY Stock Price History

PGNY Stock News Headlines

KeyBanc Reaffirms Their Buy Rating on Progyny (PGNY)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Progyny Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Progyny, Inc. Announces Fourth Quarter 2023 Results
Progyny (NASDAQ:PGNY) Now Covered by Analysts at SVB Leerink
Progyny (PGNY) to Release Quarterly Earnings on Tuesday
PGNY Mar 2024 40.000 put
Progyny Expands its Leadership Team
Truist Financial Keeps Their Buy Rating on Progyny (PGNY)
Progyny Inc CFO Mark Livingston Sells 12,368 Shares
See More Headlines
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
2/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
393
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$48.30
High Stock Price Target
$57.00
Low Stock Price Target
$43.00
Potential Upside/Downside
+39.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$30.36 million
Pretax Margin
5.67%

Debt

Sales & Book Value

Annual Sales
$786.91 million
Cash Flow
$0.30 per share
Book Value
$4.06 per share

Miscellaneous

Free Float
82,419,000
Market Cap
$3.32 billion
Optionable
Optionable
Beta
1.51

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














PGNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Progyny stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PGNY shares.
View PGNY analyst ratings
or view top-rated stocks.

What is Progyny's stock price target for 2024?

10 brokerages have issued 12 month price targets for Progyny's shares. Their PGNY share price targets range from $43.00 to $57.00. On average, they predict the company's stock price to reach $48.30 in the next twelve months. This suggests a possible upside of 39.4% from the stock's current price.
View analysts price targets for PGNY
or view top-rated stocks among Wall Street analysts.

How have PGNY shares performed in 2024?

Progyny's stock was trading at $37.18 at the beginning of the year. Since then, PGNY stock has decreased by 6.8% and is now trading at $34.65.
View the best growth stocks for 2024 here
.

When is Progyny's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PGNY earnings forecast
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings results on Tuesday, February, 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.04. The firm had revenue of $269.94 million for the quarter, compared to analysts' expectations of $274.08 million. Progyny had a trailing twelve-month return on equity of 11.64% and a net margin of 5.03%. The business's revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 earnings per share.

What guidance has Progyny issued on next quarter's earnings?

Progyny issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.330-0.350 for the period, compared to the consensus EPS estimate of 0.180. The company issued revenue guidance of $285.0 million-$292.0 million, compared to the consensus revenue estimate of $314.0 million.

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny Chief Executive Officer David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Progyny's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.63%), International Assets Investment Management LLC (6.13%), Clearbridge Investments LLC (3.64%), Jennison Associates LLC (2.64%), Riverbridge Partners LLC (2.10%) and Riverbridge Partners LLC (1.91%). Insiders that own company stock include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Kevin K Gordon, Lisa Greenbaum, Mark S Livingston, Michael E Sturmer, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Robert Michael Floyd and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PGNY) was last updated on 2/28/2024 by MarketBeat.com Staff